Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?

Abstract: Current pharmacological treatment of insomnia involves the use of sedative-hypnotic benzodiazepine and non-benzodiazepine drugs. Although benzodiazepines improve sleep, their multiple adverse effects hamper their application. Adverse effects include impairment of memory and cognitive funct...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Srinivasan, Venkataramanujan, Brzezinski, Amnon, Pandi Perumal, Seithikurippu R., Spence, David Warren, Cardinali, Daniel Pedro, Brown, Gregory M.
Formato: Artículo
Lenguaje:Inglés
Inglés
Publicado: Elsevier 2019
Materias:
MELATONINA
AGONISTAS
INSOMNIO
DEPRESION
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/1609
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-1609
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
Inglés
topic MELATONINA
AGONISTAS
INSOMNIO
DEPRESION
spellingShingle MELATONINA
AGONISTAS
INSOMNIO
DEPRESION
Srinivasan, Venkataramanujan
Brzezinski, Amnon
Pandi Perumal, Seithikurippu R.
Spence, David Warren
Cardinali, Daniel Pedro
Brown, Gregory M.
Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
topic_facet MELATONINA
AGONISTAS
INSOMNIO
DEPRESION
description Abstract: Current pharmacological treatment of insomnia involves the use of sedative-hypnotic benzodiazepine and non-benzodiazepine drugs. Although benzodiazepines improve sleep, their multiple adverse effects hamper their application. Adverse effects include impairment of memory and cognitive functions, nextday hangover and dependence. Non-benzodiazepines are effective for initiating sleep but are not as effective as benzodiazepines for improving sleep quality or efficiency. Furthermore, their prolonged use produces adverse effects similar to those observed with benzodiazepines. Inasmuch as insomnia may be associated with decreased nocturnal melatonin, administration of melatonin is a strategy that has been increasingly used for treating insomnia. Melatonin can be effective for improving sleep quality without the adverse effects associated with hypnotic-sedatives. Ramelteon, a synthetic analog of melatonin which has a longer half life and a stronger affinity for MT1 and MT2 melatonergic receptors, has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, dependence, or cognitive impairment. Insomnia is also a major complaint among patients suffering from depressive disorders and is often aggravated by conventional antidepressants especially the specific serotonin reuptake inhibitors. The novel antidepressant agomelatine, a dual action agent with affinity for melatonin MT1 and MT2 receptors and 5-HT2c antagonistic properties, constitutes a new approach to the treatment of major depressive disorders. Agomelatine ameliorates the symptoms of depression and improves the quality and efficiency of sleep. Taken together, the evidence indicates that MT1 / MT2 receptor agonists like ramelteon or agomelatine may be valuable pharmacological tools for insomnia and for depression-associated insomnia.
format Artículo
author Srinivasan, Venkataramanujan
Brzezinski, Amnon
Pandi Perumal, Seithikurippu R.
Spence, David Warren
Cardinali, Daniel Pedro
Brown, Gregory M.
author_facet Srinivasan, Venkataramanujan
Brzezinski, Amnon
Pandi Perumal, Seithikurippu R.
Spence, David Warren
Cardinali, Daniel Pedro
Brown, Gregory M.
author_sort Srinivasan, Venkataramanujan
title Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
title_short Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
title_full Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
title_fullStr Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
title_full_unstemmed Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
title_sort melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics?
publisher Elsevier
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/1609
work_keys_str_mv AT srinivasanvenkataramanujan melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
AT brzezinskiamnon melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
AT pandiperumalseithikurippur melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
AT spencedavidwarren melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
AT cardinalidanielpedro melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
AT browngregorym melatoninagonistsinprimaryinsomniaanddepressionassociatedinsomniaaretheysuperiortosedativehypnotics
bdutipo_str Repositorios
_version_ 1764820525705592832

Ejemplares similares